140 related articles for article (PubMed ID: 34651220)
1. Preclinical characterization of [
Koike T; Constantinescu CC; Ikeda S; Nishi T; Sunahara E; Miyamoto M; Cole P; Barret O; Alagille D; Papin C; Morley T; Fowles K; Seibyl J; Tamagnan G; Kuroita T
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1148-1156. PubMed ID: 34651220
[TBL] [Abstract][Full Text] [Related]
2. Clinical Characterization of [
Constantinescu CC; Brown T; Wang S; Yin W; Barret O; Jennings D; Tauscher J
J Nucl Med; 2023 Dec; 64(12):1972-1979. PubMed ID: 37770111
[TBL] [Abstract][Full Text] [Related]
3. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice.
Nishi T; Kondo S; Miyamoto M; Watanabe S; Hasegawa S; Kondo S; Yano J; Watanabe E; Ishi T; Yoshikawa M; Ando HK; Farnaby W; Fujimoto S; Sunahara E; Ohori M; During MJ; Kuroita T; Koike T
Sci Rep; 2020 Oct; 10(1):17081. PubMed ID: 33051477
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of aryl-piperidine derivatives as potent and selective PET tracers for cholesterol 24-hydroxylase (CH24H).
Ikeda S; Kajita Y; Miyamoto M; Matsumiya K; Ishii T; Nishi T; Gay SC; Lane W; Constantinescu CC; Alagille D; Papin C; Tamagnan G; Kuroita T; Koike T
Eur J Med Chem; 2022 Oct; 240():114612. PubMed ID: 35863274
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Soticlestat, a Potent and Selective Inhibitor for Cholesterol 24-Hydroxylase (CH24H).
Koike T; Yoshikawa M; Ando HK; Farnaby W; Nishi T; Watanabe E; Yano J; Miyamoto M; Kondo S; Ishii T; Kuroita T
J Med Chem; 2021 Aug; 64(16):12228-12244. PubMed ID: 34387987
[TBL] [Abstract][Full Text] [Related]
6. Anticonvulsive properties of soticlestat, a novel cholesterol 24-hydroxylase inhibitor.
Nishi T; Metcalf CS; Fujimoto S; Hasegawa S; Miyamoto M; Sunahara E; Watanabe S; Kondo S; White HS
Epilepsia; 2022 Jun; 63(6):1580-1590. PubMed ID: 35316533
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Novel 3-Piperidinyl Pyridine Derivatives as Highly Potent and Selective Cholesterol 24-Hydroxylase (CH24H) Inhibitors.
Kajita Y; Ikeda S; Yoshikawa M; Fukuda H; Watanabe E; Yano J; Lane W; Miyamoto M; Ishii T; Nishi T; Koike T
J Med Chem; 2022 Feb; 65(4):3343-3358. PubMed ID: 35166541
[TBL] [Abstract][Full Text] [Related]
8. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice.
Hawkins NA; Jurado M; Thaxton TT; Duarte SE; Barse L; Tatsukawa T; Yamakawa K; Nishi T; Kondo S; Miyamoto M; Abrahams BS; During MJ; Kearney JA
Epilepsia; 2021 Nov; 62(11):2845-2857. PubMed ID: 34510432
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics, enzyme occupancy, and 24S-hydroxycholesterol modeling of soticlestat, a novel cholesterol 24-hydroxylase inhibitor, in healthy adults.
Yin W; Facius A; Wagner T; Tsai M; Asgharnejad M; Lahu G; Vakilynejad M
Clin Transl Sci; 2023 Jul; 16(7):1149-1162. PubMed ID: 37212649
[TBL] [Abstract][Full Text] [Related]
10. Characterization of soticlestat, a novel cholesterol 24-hydroxylase inhibitor, in acute and chronic neurodegeneration models.
Hasegawa S; Watanabe S; Fujimoto S; Kondo S; Nishi T
Neurosci Res; 2024 Jun; ():. PubMed ID: 38897234
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics, enzyme occupancy, and pharmacodynamic modeling of soticlestat in patients with developmental and epileptic encephalopathies.
Yin W; Facius A; Asgharnejad M; Lahu G; Vakilynejad M
Clin Transl Sci; 2024 Mar; 17(3):e13722. PubMed ID: 38445548
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol 24-hydroxylase is a novel pharmacological target for anti-ictogenic and disease modification effects in epilepsy.
Salamone A; Terrone G; Di Sapia R; Balosso S; Ravizza T; Beltrame L; Craparotta I; Mannarino L; Cominesi SR; Rizzi M; Pauletti A; Marchini S; Porcu L; Zimmer TS; Aronica E; During M; Abrahams B; Kondo S; Nishi T; Vezzani A
Neurobiol Dis; 2022 Oct; 173():105835. PubMed ID: 35932989
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects.
Wang S; Chen G; Merlo Pich E; Affinito J; Cwik M; Faessel H
Br J Clin Pharmacol; 2021 Nov; 87(11):4354-4365. PubMed ID: 33837574
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Evaluation of 18F-PF-05270430, a Novel PET Radioligand for the Phosphodiesterase 2A Enzyme.
Chen L; Nabulsi N; Naganawa M; Zasadny K; Skaddan MB; Zhang L; Najafzadeh S; Lin SF; Helal CJ; Boyden TL; Chang C; Ropchan J; Carson RE; Villalobos A; Huang Y
J Nucl Med; 2016 Sep; 57(9):1448-53. PubMed ID: 27199356
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Evaluation and Nonhuman Primate Receptor Occupancy Study of
Kolb HC; Barret O; Bhattacharya A; Chen G; Constantinescu C; Huang C; Letavic M; Tamagnan G; Xia CA; Zhang W; Szardenings AK
J Nucl Med; 2019 Aug; 60(8):1154-1159. PubMed ID: 30733317
[TBL] [Abstract][Full Text] [Related]
16. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, modifies acute seizure burden and chronic epilepsy-related behavioral deficits following Theiler's virus infection in mice.
Barker-Haliski M; Nishi T; White HS
Neuropharmacology; 2023 Jan; 222():109310. PubMed ID: 36341806
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of [¹⁸F]MK-0911, a positron emission tomography (PET) tracer for opioid receptor-like 1 (ORL1), in rhesus monkey and human.
Hostetler ED; Sanabria-Bohórquez S; Eng W; Joshi AD; Patel S; Gibson RE; O'Malley S; Krause SM; Ryan C; Riffel K; Bi S; Okamoto O; Kawamoto H; Ozaki S; Ohta H; de Groot T; Bormans G; Depré M; de Hoon J; De Lepeleire I; Reynders T; Cook JJ; Burns HD; Egan M; Cho W; van Laere K; Hargreaves RJ
Neuroimage; 2013 Mar; 68():1-10. PubMed ID: 23238431
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers.
Wang S; Chen G; Merlo Pich E; Affinito J; Cwik M; Faessel HM
Br J Clin Pharmacol; 2022 Jun; 88(6):2899-2908. PubMed ID: 35001412
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a PET Radioligand to Image
Paul S; Haskali MB; Liow JS; Zoghbi SS; Barth VN; Kolodrubetz MC; Bond MR; Morse CL; Gladding RL; Frankland MP; Kant N; Slieker L; Shcherbinin S; Nuthall HN; Zanotti-Fregonara P; Hanover JA; Jesudason C; Pike VW; Innis RB
J Nucl Med; 2019 Jan; 60(1):129-134. PubMed ID: 30213846
[TBL] [Abstract][Full Text] [Related]
20. A phase 1b/2a study of soticlestat as adjunctive therapy in participants with developmental and/or epileptic encephalopathies.
Halford JJ; Sperling MR; Arkilo D; Asgharnejad M; Zinger C; Xu R; During M; French JA
Epilepsy Res; 2021 Aug; 174():106646. PubMed ID: 33940389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
